Phytonutrients and Neurological Disorders

Prof. Dr. Haroon Khan has obtained the degree of B. Pharm (1999), M. Phil (2005), and PhD (2011) from the Department of Pharmacy, University of Peshawar. He started his career as a lecturer from the Gandhara College of Pharmacy, Gandhara University, Peshawar and currently, Professor of Pharmacy at the Department of Pharmacy, Abdul Wali Khan University Mardan, Pakistan. He has more than seventeen years of experience in pharmacy teaching, research and professional expertise in various fields of pharmaceutical sciences. Dr. Khan has 162 publications, including research, review, and editorial in various national and international reputable journals with considerable impact factor while several others are submitted or in the process of submission. His research focus is phytomedicines including phytopharmacological and phytochemical investigations of extracts/isolated compounds in collaboration with numerous national and international research groups. The scientific contribution of Dr. Khan has been acknowledged by the Pakistan Council for Science and Pakistan Council for Science and Technology (PCST) and awarded Research Productivity four times 2011-2014. He has also published three books with LAMBERT Academic publishers, Germany and four chapters. He is also the editorial board member of various international journals. Additionally, he is supervising many post-graduate scholars in various research projects. Dr. Michael Aschner is currently the Harold and Muriel Block Chair in Molecular Pharmacology at Albert Einstein College of Medicine where he is also a Professor in the Departments of Molecular Pharmacology, Neuroscience, and Pediatrics. He is a leading expert in neurotoxicology and neurodevelopmental and neurodegenerative diseases. In addition to serving as a past president of the Society of Toxicology (2022-23), he served on numerous toxicology panels (U.S. EPA and CDC), been an expert reviewer for multiple federal agencies in the US and abroad, and is a member of the Neurotoxicology and Alcohol study section (NIH). He is a past recipient of the prestigious Society of Toxicology Merit Award (2010) and the Distinguished Neurotoxicologist Award (2020). He is a co-editor of the Elsevier series, Advancements in Neurotoxicology in addition to edited other Elsevier titles. He has published numerous articles and has served as an associate editor for multiple high impact factor journals.Hamed Mirzaei is a Professor at the Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Iran.

"...provides a good introduction to plant-based nutraceuticals in neurological disorders [and] helps the reader understand the many different plant derivatives, including polyphenols, flavones, flavanols, cathechins, and anthrocyanins. [A]ims to discuss the latest research into the role of phytonutraceuticals in neurological illnesses. [A] helpful resource for neurologists as often patients are interested in incorporating nutraceuticals in their treatment plans... [A] decent reference for phytonutraceuticals in neurological disorders. It can be a helpful resource for neurologists who are interested in advising patients about non-pharmacological plant-derived supplements." --©Doody’s Review Service, 2024, Shin Beh, MD, FAAN, FAHS (University of Texas Southwestern Medical Center at Dallas)

• Part A, Section 1: Bioactive compound classes and biosynthesis pathway1. Current therapies for neurological disorders and their limitations2. Biosynthesis of phytonutrients3. Neuroprotective effects of flavonoids4. Neuroprotective effects of glycosides5. Neuroprotective effects of terpenoids6. Neuroprotective effects of alkaloids7. Neuroprotective effects of saponins8. Neuroprotective effects of steroids9. Neuroprotective effects of essential oils10. Neuroprotective effects of phytonutrients at gene levelsPart A Section 2: General considerations11. Latest development in quality control parameters/specification in phytonutrients studies12. Phytonutrients standardization for effective therapeutic outcomes13. Phytonutrients and technological development in formulationsPart B Sections: Toxicological considerations in phytonutrientsa. Adverse drug reactionsb. Toxicokineticsc. Toxicodynamics